|Other Names||Chloride channel protein 2, ClC-2, CLCN2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6329a was selected from the C-term region of human CLCN2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport.|
|Cellular Location||Membrane; Multi-pass membrane protein.|
|Tissue Location||Ubiquitously expressed. Moderately expressed in aortic and coronary vascular smooth muscle cells and expressed at a low level in aortic endothelial cells|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CLCN2 is a voltage-gated chloride channel, a class of proteins that have several functions including the regulation of cell volume, membrane potential stabilization, signal transduction and transepithelial transport. This protein is ubiquitously expressed, with moderate expression in aortic and coronary vascular smooth muscle cells and low levels expressed in aortic endothelial cells. Defects in CLCN2 may be the cause of epilepsy with grand mal seizures on awakening, childhood absence epilepsy type 3, and juvenile absence epilepsy. Single nucleotide polymorphisms (SNPs) of CLCN2 may also at as potential modifiers of cystic fibrosis disease severity.
Hum. Molec. Genet. 4: 407-413, 1995. Nature Genet. 33: 527-532, 2003. Hum. Molec. Genet. 9: 1465-1472, 2000.Proc. Nat. Acad. Sci. 95: 3879-3884, 1998. Neuroscience. 101: 51-65, 2000.Biochem. Biophys. Res. Commun. 95, 265-271 (2005)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.